Fresenius Medical Care AG & Co. KGaA (FMS) Price Target Analysis
Updated Jul 2, 2026
Analyst Rating: Hold
Based on 20 analysts15.7% Below Target
FMS trades 15.7% below Wall Street's consensus target of $28.00.
Current Price$24.20
Average Target$28.00
Low$28.00
Median$28.00
High$28.00
Analyst Target Range
Forward P/E12.0x
(Value)
PEG Ratio2.35
(Pricey)
Implied Growth+17.5%
(Moderate)
Analyst Spread0.0%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes FMS achieves its forward estimates and maintains a stable P/E multiple of 12.0x. This scenario reflects the blended consensus of 20 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
FMS Price Target Analysis
Updated July 8, 2026As of July 8, 2026, Fresenius Medical Care AG & Co. KGaA (FMS) has a Wall Street consensus price target of $28.00, based on estimates from 20 covering analysts. With the stock currently trading at $24.20, this represents a potential upside of +15.7%. The company has a market capitalization of $13.32B.
Analyst price targets range from a low of $28.00 to a high of $28.00, representing a 0% spread in expectations. The median target of $28.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 5 analysts rating the stock as a Buy or Strong Buy,13 rating it Hold, and 2 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, FMS trades at a trailing P/E of 12.6x and forward P/E of 12.0x. The forward PEG ratio of 2.35 reflects a premium valuation. Analysts expect EPS to grow +17.5% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $18.36, with bear and bull scenarios of $11.56 and $24.19 respectively. Model confidence stands at 47/100, suggesting limited visibility into future performance.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+11.5%
Industry Consensus
Avg Forward P/E
16.7x
(Fair)
Peers with Coverage
9 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 DVADaVita Inc. | $15.0B | $234.31 | $202.25 | -13.7% | Hold | 15.8x | 23 |
 FXNCFirst National Corporation | $265M | $29.30 | $21.00 | -28.3% | Buy | 12.4x | 1 |
 NKTRNektar Therapeutics | $1.5B | $74.90 | $149.60 | +99.7% | Buy | — | 33 |
 BAXBaxter International Inc. | $11.8B | $22.86 | $20.71 | -9.4% | Hold | 11.9x | 36 |
 NVANova Minerals Limited | $3M | $4.58 | — | — | — | — | — |
 NXRTNexPoint Residential Trust, Inc. | $734M | $28.94 | $26.00 | -10.2% | Hold | — | 10 |
 USPHU.S. Physical Therapy, Inc. | $1.1B | $71.80 | $96.00 | +33.7% | Buy | 25.7x | 13 |
 ACHCAcadia Healthcare Company, Inc. | $2.9B | $31.92 | $28.33 | -11.2% | Buy | 21.2x | 25 |
 ABTAbbott Laboratories | $166.9B | $95.84 | $125.62 | +31.1% | Buy | 17.5x | 41 |
 BDXBecton, Dickinson and Company | $56.6B | $156.30 | $174.81 | +11.8% | Hold | 12.4x | 34 |
FMS — Frequently Asked Questions
Quick answers to the most common questions about buying FMS stock.
What is the FMS stock price target for 2026?
Fresenius Medical Care AG & Co. KGaA (FMS) has a consensus 12-month price target of $28, implying 15.7% upside from $24.2. The 20 analysts covering FMS see moderate appreciation potential.
Is FMS a buy, sell, or hold?
FMS has a consensus rating of "Hold" based on 20 Wall Street analysts. The rating breakdown is mixed, with 13 Hold ratings making up the largest segment. The consensus 12-month price target of $28 implies 15.7% upside from current levels.
Is FMS stock overvalued or undervalued?
With a forward P/E of 11.9678x, FMS trades at a relatively low valuation. The consensus target of $28 implies 15.7% appreciation, suggesting meaningful undervaluation.
How high can FMS stock go?
The most bullish Wall Street analyst has a price target of $28 for FMS, while the most conservative target is $28. The consensus of $28 represents the median expectation. Our quantitative valuation model projects a bull case target of $24 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover FMS stock?
FMS is well covered by analysts, with 20 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 13 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the FMS stock forecast?
The 12-month FMS stock forecast based on 20 Wall Street analysts shows a consensus price target of $28, with estimates ranging from $28 (bear case) to $28 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $18, with bear/bull scenarios of $12/$24.
What is FMS's fair value based on fundamentals?
Our quantitative valuation model calculates FMS's fair value at $18 (base case), with a bear case of $12 and bull case of $24. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 47/100.
What is FMS's forward P/E ratio?
FMS trades at a forward P/E ratio of 12.0x based on next-twelve-months earnings estimates compared to a trailing P/E of 12.6x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy FMS stock?
Wall Street analysts are optimistic on FMS, with a "Hold" consensus rating and $28 price target (15.7% upside). 5 of 20 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do FMS price targets vary so much?
FMS analyst price targets range from $28 to $28, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $28 consensus represents the middle ground. Our model's $12-$24 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare